Outlook Therapeutics (NASDAQ:OTLK) Given Neutral Rating at Chardan Capital

Outlook Therapeutics (NASDAQ:OTLK)‘s stock had its “neutral” rating reiterated by investment analysts at Chardan Capital in a research report issued on Monday,Benzinga reports.

A number of other brokerages also recently issued reports on OTLK. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Outlook Therapeutics in a research note on Friday. Ascendiant Capital Markets dropped their price target on Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd. Finally, BTIG Research reduced their price objective on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research report on Friday. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $42.34.

Outlook Therapeutics Stock Up 20.6 %

OTLK stock opened at $2.05 on Monday. The firm has a market cap of $48.50 million, a price-to-earnings ratio of -0.19 and a beta of 0.62. The company’s fifty day simple moving average is $5.29 and its 200 day simple moving average is $6.70. Outlook Therapeutics has a 12-month low of $0.87 and a 12-month high of $12.85.

Insider Activity

In other Outlook Therapeutics news, CFO Lawrence A. Kenyon purchased 5,000 shares of Outlook Therapeutics stock in a transaction that occurred on Thursday, September 26th. The stock was acquired at an average price of $5.69 per share, with a total value of $28,450.00. Following the transaction, the chief financial officer now owns 5,946 shares in the company, valued at $33,832.74. This trade represents a 528.54 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 3.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Great Point Partners LLC increased its position in shares of Outlook Therapeutics by 15.0% during the second quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock worth $12,557,000 after acquiring an additional 221,510 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in Outlook Therapeutics during the 2nd quarter worth approximately $303,000. Squarepoint Ops LLC purchased a new stake in shares of Outlook Therapeutics in the second quarter worth approximately $232,000. Christensen King & Associates Investment Services Inc. bought a new position in shares of Outlook Therapeutics in the third quarter valued at approximately $55,000. Finally, AQR Capital Management LLC purchased a new position in shares of Outlook Therapeutics during the second quarter valued at approximately $75,000. 11.20% of the stock is owned by institutional investors.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.